ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

September 27, 2007 09:15 ET

ALDA Pharmaceuticals Starts Clinical Trials

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 27, 2007) - ALDA Pharmaceuticals Corp. ("ALDA" or "the Company") (TSX VENTURE:APH) announces that initial clinical trials of its T36® formulation for use as a skin antiseptic, a hygienic hand rub, a pre-surgical hand wash and a pre-injection scrub have been started. On completion, the data from the tests, along with existing and new toxicology information, will be used to support applications in Canada and Europe to test the anti-microbial effectiveness of the formulations with human volunteers. Additional non-human testing will be required before the Company can request human trials in the US. On successful completion of human trials, the Company will be able to pursue the registration and marketing of its products. Dr. Terrance Owen, President & CEO, comments, "This is a significant milestone for the company. We have identified, coordinated and started the testing protocols that are needed for the registration of our products in three major jurisdictions of the world. This simultaneous approach will save time and money and allow us to fast-track sales in Canada and Europe while completing the more extensive testing required by the US." The testing is being conducted by Bioscience Laboratories, Inc. located in Bozeman, Montana.

About Bioscience Laboratories, Inc.

BioScience Laboratories, Inc. has been providing antimicrobial product testing and result interpretation for various industries, including healthcare, pharmaceutical, personal care and consumer products for over 16 years.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp. - Distribution & Sales Contact
    Peter Chen
    CFO and Director
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp. - Investor Relations Contact
    Scott Young
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com